Q1 2025 · 13F-HR
Birchview Capital, LPholdings as filed
Filed 2025-05-15 · accession 0001618205-25-000002
$115.2M
Reported value
68
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $41.8M | 36.3% | 685,192 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $7.5M | 6.55% | 66,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $4.4M | 3.80% | 263,400 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $4.1M | 3.58% | 332,974 | Common | SOLE |
| 09075X108 | — | BIODESIX INC | $3.6M | 3.11% | 5,736,113 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $3.3M | 2.90% | 30,240 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $3.0M | 2.61% | 1,187,735 | Common | SOLE |
| 05463X106 | AXGN | AXOGEN INC | $3.0M | 2.59% | 161,000 | Common | SOLE |
| 71944F106 | PHR | PHREESIA INC | $2.9M | 2.55% | 114,700 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $2.5M | 2.15% | 138,000 | Common | SOLE |
| 74838J101 | — | QUIDELORTHO CORP | $2.4M | 2.05% | 67,619 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.3M | 2.02% | 48,002 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $2.3M | 2.01% | 7,500 | Common | SOLE |
| 256086109 | DCGO | DOCGO INC | $2.3M | 1.98% | 864,062 | Common | SOLE |
| 69047Q102 | OVV | OVINTIV INC | $2.2M | 1.94% | 52,200 | Common | SOLE |
| 415858109 | HROW | HARROW HEALTH INC | $1.9M | 1.68% | 72,910 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $1.9M | 1.63% | 11,280 | Common | SOLE |
| 26884L109 | EQT | EQT CORPORATION | $1.8M | 1.61% | 34,619 | Common | SOLE |
| 14843C105 | CSTL | CASTLE BIOSCIENCES INC | $1.8M | 1.54% | 88,404 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $1.7M | 1.43% | 50,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $1.4M | 1.21% | 210,005 | Common | SOLE |
| 89455T109 | TMCI | TREACE MEDICAL CONCEPTS INC | $1.4M | 1.20% | 164,947 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $1.1M | 0.99% | 310,930 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $940,188 | 0.82% | 88,697 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $773,199 | 0.67% | 67,002 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $704,550 | 0.61% | 21,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $699,780 | 0.61% | 6,000 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $666,444 | 0.58% | 30,006 | Common | SOLE |
| 40637H109 | HALO | HALOZYME THERAPEUTICS INC | $638,100 | 0.55% | 10,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $579,360 | 0.50% | 16,000 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $552,420 | 0.48% | 31,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORP | $514,400 | 0.45% | 16,000 | Common | SOLE |
| 68752L100 | KIDS | ORTHOPEDIATRICS CORP | $492,600 | 0.43% | 20,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $476,442 | 0.41% | 128,768 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $449,219 | 0.39% | 32,110 | Common | SOLE |
| 88025U109 | TXG | 10X GENOMICS INC | $436,500 | 0.38% | 50,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $401,900 | 0.35% | 10,000 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $365,396 | 0.32% | 8,280 | Common | SOLE |
| 745848101 | LUNG | PULMONX CORP | $343,230 | 0.30% | 51,000 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $339,000 | 0.29% | 60,000 | Common | SOLE |
| 02081G201 | ATEC | ALPHATEC HOLDINGS INC | $334,620 | 0.29% | 33,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $325,624 | 0.28% | 40,300 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $312,560 | 0.27% | 8,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $306,180 | 0.27% | 14,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $300,000 | 0.26% | 40,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $298,880 | 0.26% | 8,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $276,640 | 0.24% | 26,000 | Common | SOLE |
| 690145107 | OMGBP | OUTSET MEDICAL INC | $271,899 | 0.24% | 24,584 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $238,977 | 0.21% | 2,700 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $228,480 | 0.20% | 28,000 | Common | SOLE |
| 00430H102 | — | ACCELERATE DIAGNOSTICS INC | $227,992 | 0.20% | 325,239 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $210,600 | 0.18% | 30,000 | Common | SOLE |
| 641288105 | NPCE | NEUROPACE INC | $202,072 | 0.18% | 16,442 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $189,100 | 0.16% | 155,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $152,850 | 0.13% | 15,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $151,994 | 0.13% | 138,176 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $151,400 | 0.13% | 20,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $147,687 | 0.13% | 10,013 | Common | SOLE |
| 25459W102 | TECL | DIREXION DAILY PHARMACEUTICAL & MEDICAL BULL 3X SH | $144,400 | 0.13% | 20,000 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $130,680 | 0.11% | 22,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $130,350 | 0.11% | 16,500 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $104,664 | 0.09% | 27,985 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $76,570 | 0.07% | 15,500 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $61,400 | 0.05% | 10,000 | Common | SOLE |
| N44821101 | IFRX | INFLARX NV | $51,000 | 0.04% | 50,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $45,600 | 0.04% | 24,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $33,120 | 0.03% | 28,800 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $27,030 | 0.02% | 17,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.